![2019 05 21 17 23 2291 Liquid Biopsy Labs Test Tubes 400](https://img.labpulse.com/files/base/smg/all/image/2019/05/lp.2019_05_21_17_23_2291_Liquid_Biopsy_Labs_test_tubes_400.png?auto=format%2Ccompress&q=70&w=400)
British Columbia-based precision medicine company Cancer Treatment Options and Management has spun off a new company called Liquid Biopsy Labs as a provider of tests that measure and analyze the source of DNA in blood.
![Liquid Biopsy Labs' technology measures and analyzes the source of DNA in blood. Image courtesy of Cancer Treatment Options and Management.](https://img.labpulse.com/files/base/smg/all/image/2019/05/lp.2019_05_21_17_23_2135_Liquid_Biopsy_Labs_test_tubes.png?auto=format%2Ccompress&fit=max&q=70&w=400)
The company sees the ability of its technology to analyze whether DNA came from live cells, dead cells, normal cells, or extracellular vesicles as a feature that differentiates it from other commercial liquid biopsy tests. For example, live cells circulating in the blood indicate metastasis, whereas the presence of dead cells show that a particular treatment is working.
The company's liquid biopsy technology may be helpful for predicting response to treatment with immunotherapy and identifying driver mutations of cancer, according to the company.